Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT03218488

A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis

Sponsor: Janssen-Cilag International NV

View on ClinicalTrials.gov

Summary

The purpose of this study is to monitor the long-term safety of ustekinumab in pediatric participants (6 years to 17 years of age at the time of inclusion) with moderate to severe plaque psoriasis, through monitoring for the following adverse events potentially related to immune modulation: serious infections, malignancies and autoimmunity; and to monitor the long-term effects of ustekinumab on growth (weight, height, body mass index) and development (sexual maturity based on the Tanner Scale).

Official title: An Observational Post-authorization Safety Study of Ustekinumab in the Treatment of Pediatric Patients Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis

Key Details

Gender

All

Age Range

6 Years - 17 Years

Study Type

OBSERVATIONAL

Enrollment

135

Start Date

2017-10-25

Completion Date

2032-08-31

Last Updated

2026-03-13

Healthy Volunteers

No

Conditions

Interventions

DRUG

Ustekinumab

Participants will not receive any intervention as part of this study. Participants with moderate to severe plaque psoriasis who are initiating treatment with ustekinumab in clinical practice (patients should either start therapy with ustekinumab within 2 months after the first assessment in the study or have started therapy with ustekinumab in the 12-week period before the first assessment in the study for the treatment of psoriasis) will be observed for the long-term safety of ustekinumab and the long-term effects of ustekinumab on growth and development.

Locations (30)

Uniklinik Graz

Graz, Austria

UCL Hopital Saint-Luc

Brussels, Belgium

UZ Leuven

Leuven, Belgium

CHU de Liège - Domaine Universitaire du Sart Tilman

Liège, Belgium

Grand Hôpital de Charleroi

Loverval, Belgium

Bispebjerg Hospital

Copenhagen, Denmark

Gentofte Herlev Hospital

Hellerup, Denmark

CH Victor Dupouy Argenteuil

Argenteuil, France

CHRU Besancon Hopital Jean Minjoz

Besançon, France

Groupe Hospitalier Pellegrin CHU de Bordeaux

Bordeaux, France

ICH Hopital A. Morvan

Brest, France

Le Bateau Blanc

Martigues, France

Hopital Necker Enfants Malades

Paris, France

CHU Saint Etienne Hopital Nord

Saint-Etienne, France

Praxis Dr. med. Beate Schwarz - Germany

Langenau, Germany

Gemeinschaftspraxis Dres. Quist

Mainz, Germany

Universitatsmedizin der Johannes Gutenberg Universitat Mainz

Mainz, Germany

Andreas Sygros Hospital

Athens, Greece

University Hospital for Skin and Venereal Diseases

Thessaloniki, Greece

Radboudumc

Nijmegen, Netherlands

Oslo universitetssykehus HF, Rikshospitalet

Oslo, Norway

Moscow Research-Practical Center of Dermatovenerology and Cosmetology

Moscow, Russia

FSBI 'Scientific Centre of Children Health' of the Russian Academy of Medical Sciences

Moscow, Russia

Llc Ultramed

Omsk, Russia

Saint-Petersburg State Pediatric Medical Academy of RosZdrav

Saint Petersburg, Russia

Kinderspital Zürich

Zurich, Switzerland

University Hospital of Wales

Cardiff, United Kingdom

Whipps Cross University Hospital

London, United Kingdom

Great Ormond Street Hospital

London, United Kingdom

Salford Royal Hospital

Salford, United Kingdom